Índice Bovespa

US Dollar vs BRL

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

TVTX Travere Therapeutics Inc

17,50

0,00 (0,00%)

Pré-mercado

Última atualização: 05:33:06

Atrasado em 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

09/30/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

03/15/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jeffrey Meckler

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Travere Therapeutics (NASDAQ:TVTX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024

Click aqui para mais gráficos Travere Therapeutics.

Travere Therapeutics (NASDAQ:TVTX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024

Click aqui para mais gráficos Travere Therapeutics.

Notícias Travere Therapeutics Inc

Form 424B5 - Prospectus [Rule 424(b)(5)]
Quinta, 31 de Outubro de 2024 (22 horas atrás) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Quinta, 31 de Outubro de 2024 (22 horas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quinta, 31 de Outubro de 2024 (22 horas atrás) • Edgar (US Regulatory)

Travere Therapeutics Reports Third Quarter 2024 Financial Results
Quinta, 31 de Outubro de 2024 (23 horas atrás) • GlobeNewswire Inc.

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
Sábado, 26 de Outubro de 2024 (6 dias atrás) • GlobeNewswire Inc.

Travere Therapeutics to Report Third Quarter 2024 Financial Results
Segunda, 21 de Outubro de 2024 (2 semanas atrás) • GlobeNewswire Inc.

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Quinta, 17 de Outubro de 2024 (2 semanas atrás) • GlobeNewswire Inc.

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Quinta, 17 de Outubro de 2024 (2 semanas atrás) • PR Newswire (US)

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
Segunda, 14 de Outubro de 2024 (3 semanas atrás) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Segunda, 30 de Setembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Segunda, 30 de Setembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Quinta, 26 de Setembro de 2024 (1 mês atrás) • Edgar (US Regulatory)

Mais Notícias de Travere Therapeutics Inc

BNP Paribas Issuance

BNP Paribas Issuance

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições